A phase II study of topical ceramides for cutaneous breast cancer

Aminah Jatoi, Vera Jean Suman, Paul Schaefer, Margaret Block, Charles Lawrence Loprinzi, Patrick Roche, Stuart Garneau, Roscoe Morton, Philip J. Stella, Steven Robert Alberts, Mark Pittelkow, Jeff A Sloan, Richard Pagano

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose. Short chain ceramides induce tumor cell apoptosis in preclinical models. Limited therapeutic options for patients with cutaneous breast cancer prompted the testing of these sphingolipids in patients with this disease. Patients and methods. Twenty-five patients with refractory, cutaneous breast cancer were treated twice a day with a 1% mixture of topical C2 and C6 ceramides administered in a 1:1 ratio. For the first 8 weeks, patients were not allowed to receive other antineoplastic therapy. In addition to tumor status and toxicity assessment throughout the trial, skin biopsies for evidence of apoptosis and quality of life questionnaires (FACT-BR) were completed at baseline and 1 month. Results. Only one patient manifested a partial response with topical ceramides, yielding a response rate of 4% (90% confidence interval 0, 17.6%). Median cutaneous progression-free survival was 2 months [4]. The topical ceramides were also well tolerated, with no grade 3 or 4 toxicity reported. None of the six patients who underwent serial skin biopsies showed increased tumor cell apoptosis morphologically or by the modified TUNEL assay. Conclusion. To our knowledge, this trial is one of the first clinical investigations of short chain ceramides. This trial's results are not promising enough to merit further study of ceramides in the manner prescribed.

Original languageEnglish (US)
Pages (from-to)99-104
Number of pages6
JournalBreast Cancer Research and Treatment
Volume80
Issue number1
DOIs
StatePublished - Jul 2003

Fingerprint

Ceramides
Skin Neoplasms
Breast Neoplasms
Apoptosis
Skin
Biopsy
Neoplasms
Sphingolipids
In Situ Nick-End Labeling
Antineoplastic Agents
Disease-Free Survival
Quality of Life
Confidence Intervals
Therapeutics

Keywords

  • Apoptosis
  • Ceramides
  • Clinical trial
  • Cutaneous cancer
  • Quality of life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II study of topical ceramides for cutaneous breast cancer. / Jatoi, Aminah; Suman, Vera Jean; Schaefer, Paul; Block, Margaret; Loprinzi, Charles Lawrence; Roche, Patrick; Garneau, Stuart; Morton, Roscoe; Stella, Philip J.; Alberts, Steven Robert; Pittelkow, Mark; Sloan, Jeff A; Pagano, Richard.

In: Breast Cancer Research and Treatment, Vol. 80, No. 1, 07.2003, p. 99-104.

Research output: Contribution to journalArticle

Jatoi, A, Suman, VJ, Schaefer, P, Block, M, Loprinzi, CL, Roche, P, Garneau, S, Morton, R, Stella, PJ, Alberts, SR, Pittelkow, M, Sloan, JA & Pagano, R 2003, 'A phase II study of topical ceramides for cutaneous breast cancer', Breast Cancer Research and Treatment, vol. 80, no. 1, pp. 99-104. https://doi.org/10.1023/A:1024409123726
Jatoi, Aminah ; Suman, Vera Jean ; Schaefer, Paul ; Block, Margaret ; Loprinzi, Charles Lawrence ; Roche, Patrick ; Garneau, Stuart ; Morton, Roscoe ; Stella, Philip J. ; Alberts, Steven Robert ; Pittelkow, Mark ; Sloan, Jeff A ; Pagano, Richard. / A phase II study of topical ceramides for cutaneous breast cancer. In: Breast Cancer Research and Treatment. 2003 ; Vol. 80, No. 1. pp. 99-104.
@article{ccef0a9a4027433bac59f6135c454e6f,
title = "A phase II study of topical ceramides for cutaneous breast cancer",
abstract = "Purpose. Short chain ceramides induce tumor cell apoptosis in preclinical models. Limited therapeutic options for patients with cutaneous breast cancer prompted the testing of these sphingolipids in patients with this disease. Patients and methods. Twenty-five patients with refractory, cutaneous breast cancer were treated twice a day with a 1{\%} mixture of topical C2 and C6 ceramides administered in a 1:1 ratio. For the first 8 weeks, patients were not allowed to receive other antineoplastic therapy. In addition to tumor status and toxicity assessment throughout the trial, skin biopsies for evidence of apoptosis and quality of life questionnaires (FACT-BR) were completed at baseline and 1 month. Results. Only one patient manifested a partial response with topical ceramides, yielding a response rate of 4{\%} (90{\%} confidence interval 0, 17.6{\%}). Median cutaneous progression-free survival was 2 months [4]. The topical ceramides were also well tolerated, with no grade 3 or 4 toxicity reported. None of the six patients who underwent serial skin biopsies showed increased tumor cell apoptosis morphologically or by the modified TUNEL assay. Conclusion. To our knowledge, this trial is one of the first clinical investigations of short chain ceramides. This trial's results are not promising enough to merit further study of ceramides in the manner prescribed.",
keywords = "Apoptosis, Ceramides, Clinical trial, Cutaneous cancer, Quality of life",
author = "Aminah Jatoi and Suman, {Vera Jean} and Paul Schaefer and Margaret Block and Loprinzi, {Charles Lawrence} and Patrick Roche and Stuart Garneau and Roscoe Morton and Stella, {Philip J.} and Alberts, {Steven Robert} and Mark Pittelkow and Sloan, {Jeff A} and Richard Pagano",
year = "2003",
month = "7",
doi = "10.1023/A:1024409123726",
language = "English (US)",
volume = "80",
pages = "99--104",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A phase II study of topical ceramides for cutaneous breast cancer

AU - Jatoi, Aminah

AU - Suman, Vera Jean

AU - Schaefer, Paul

AU - Block, Margaret

AU - Loprinzi, Charles Lawrence

AU - Roche, Patrick

AU - Garneau, Stuart

AU - Morton, Roscoe

AU - Stella, Philip J.

AU - Alberts, Steven Robert

AU - Pittelkow, Mark

AU - Sloan, Jeff A

AU - Pagano, Richard

PY - 2003/7

Y1 - 2003/7

N2 - Purpose. Short chain ceramides induce tumor cell apoptosis in preclinical models. Limited therapeutic options for patients with cutaneous breast cancer prompted the testing of these sphingolipids in patients with this disease. Patients and methods. Twenty-five patients with refractory, cutaneous breast cancer were treated twice a day with a 1% mixture of topical C2 and C6 ceramides administered in a 1:1 ratio. For the first 8 weeks, patients were not allowed to receive other antineoplastic therapy. In addition to tumor status and toxicity assessment throughout the trial, skin biopsies for evidence of apoptosis and quality of life questionnaires (FACT-BR) were completed at baseline and 1 month. Results. Only one patient manifested a partial response with topical ceramides, yielding a response rate of 4% (90% confidence interval 0, 17.6%). Median cutaneous progression-free survival was 2 months [4]. The topical ceramides were also well tolerated, with no grade 3 or 4 toxicity reported. None of the six patients who underwent serial skin biopsies showed increased tumor cell apoptosis morphologically or by the modified TUNEL assay. Conclusion. To our knowledge, this trial is one of the first clinical investigations of short chain ceramides. This trial's results are not promising enough to merit further study of ceramides in the manner prescribed.

AB - Purpose. Short chain ceramides induce tumor cell apoptosis in preclinical models. Limited therapeutic options for patients with cutaneous breast cancer prompted the testing of these sphingolipids in patients with this disease. Patients and methods. Twenty-five patients with refractory, cutaneous breast cancer were treated twice a day with a 1% mixture of topical C2 and C6 ceramides administered in a 1:1 ratio. For the first 8 weeks, patients were not allowed to receive other antineoplastic therapy. In addition to tumor status and toxicity assessment throughout the trial, skin biopsies for evidence of apoptosis and quality of life questionnaires (FACT-BR) were completed at baseline and 1 month. Results. Only one patient manifested a partial response with topical ceramides, yielding a response rate of 4% (90% confidence interval 0, 17.6%). Median cutaneous progression-free survival was 2 months [4]. The topical ceramides were also well tolerated, with no grade 3 or 4 toxicity reported. None of the six patients who underwent serial skin biopsies showed increased tumor cell apoptosis morphologically or by the modified TUNEL assay. Conclusion. To our knowledge, this trial is one of the first clinical investigations of short chain ceramides. This trial's results are not promising enough to merit further study of ceramides in the manner prescribed.

KW - Apoptosis

KW - Ceramides

KW - Clinical trial

KW - Cutaneous cancer

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0038160944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038160944&partnerID=8YFLogxK

U2 - 10.1023/A:1024409123726

DO - 10.1023/A:1024409123726

M3 - Article

C2 - 12889603

AN - SCOPUS:0038160944

VL - 80

SP - 99

EP - 104

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -